OlodaterolHydrochloride , 10mMinDMSO , 869477-96-3
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB224.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 153-155°C |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| color | Off-White to Pale Beige |
| Water Solubility | Water : 250 mg/mL (591.16 mM; Need ultrasonic) |
| Stability: | Hygroscopic |
Description and Uses
Olodaterol hydrochloride was approved for long-term, oncedaily maintenance treatment of chronic obstructive pulmonary disease (COPD) in 2013 in the following countries: Canada, Russia, United Kingdom, Denmark, and Iceland. The drug has been recommended by a federal advisory panel for approval by the FDA. Developed and marketed by Boehringer Ingelheim, olodaterol is a long-acting b2-adrenergic receptor agonist with high selectivity over the b1- and b3-receptors (219- and 1622-fold, respectively). Upon binding to and activating the b2-adrenergic receptor in the airway, olodaterol stimulates adenyl cyclase to synthesize cAMP, leading to the relaxation of smooth muscle cells in the airway. Administered by inhalation using the Respimat® Soft Mist inhaler, it delivers significant bronchodilator effects within five minutes of the first dose and provides sustained improvement in forced expiratory volume (FEV1) for over 24 h.
Olodaterol is a long acting β-adrenoceptor agonist used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD).
Safety
| Symbol(GHS) |   GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H319-H361-H302-H372 |
| Precautionary statements | P264-P280-P305+P351+P338-P337+P313P-P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P312-P330-P501-P260-P264-P270-P314-P501 |
